

Livmoniplimab Biosimilar - Research Grade

Product Code: ICH5255

More Information

Species Reactivity: Human

Target: TGFB1, LRRC32

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Livmoniplimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01137;Q14392

Shipping Conditions: Blue ice

background: This is an unconjugated, non-therapeutic recombinant analog of livmoniplimab, supplied strictly for research use only. It is built as a human IgG4-kappa molecule directed against the GARP:latent-TGFβ1 complex, reproducing the target specificity of the originator drug so that laboratories can study GARP-mediated latent-TGFβ1 presentation and activation in controlled settings. It is not the clinical product and is not intended for human or veterinary use. Typical research applications include use as a binding and neutralisation reagent, an isotype-matched positive control in complex-directed assays, a benchmarking tool alongside other anti-GARP/TGFβ reagents, and a starting point for ADCC or antibody-engineering workflows. The material is offered at research grade with low endotoxin (1 EU/mg research grade; 0.5 EU/mg ultra-low option) and is available in bulk milligram-to-gram quantities to support in-vitro assay development, preclinical

characterisation, and formulation studies. Because it is a defined recombinant human IgG4, it provides lot-consistent performance for reproducible comparative work. Guidance is provided for ichorbio to review before publication. GARP (glycoprotein A repetitions predominant), encoded by LRRC32, is a transmembrane leucine-rich-repeat protein that acts as a cell-surface docking receptor for latent TGF β . It binds the latency-associated peptide (LAP) of pro-TGF β 1 (encoded by TGFB1) via disulfide bonds, tethering the latent complex to the membrane of regulatory T cells, activated platelets, and other cell types. This GARP:latent-TGF β 1 complex concentrates the cytokine at the cell surface and, together with integrins and mechanical force, promotes release of mature, active TGF β 1. Active TGF β 1 signals through TGFBR1/TGFBR2 and SMAD pathways to drive immunosuppression, Treg function, fibrosis, and tissue homeostasis. In tumours, GARP-dependent TGF β 1 activation contributes to an immunosuppressive microenvironment, making the surface-restricted GARP:latent-TGF β 1 complex an attractive, cell-context-specific target compared with systemic TGF β neutralisation.

Other names: Garpin, Glycoprotein A repetitions predominant, GARP, Leucine-rich repeat-containing protein 32, Transforming growth factor beta-1 proprotein, Transforming growth factor beta activator LRRC32, TGFB1, TGFB, LRRC32, D11S833E

Specificity: Detects human TGFB1, LRRC32

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.



Delivery Time: 4 weeks